190 related articles for article (PubMed ID: 26941130)
21. ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany.
Iking-Konert C; von Hinüber U; Richter C; Schwenke H; Gürtler I; Kästner P; Klapperich B; Peters MA; Burmester GR
Rheumatology (Oxford); 2016 Apr; 55(4):624-35. PubMed ID: 26515959
[TBL] [Abstract][Full Text] [Related]
22. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
[TBL] [Abstract][Full Text] [Related]
23. Glucocorticoid-sparing effect of first-year anti-TNFα treatment in rheumatoid arthritis (CORPUS Cohort).
Duquenne C; Wendling D; Sibilia J; Job-Deslandre C; Guillevin L; Benichou J; Flipo RM; Guillemin F; Saraux A
Clin Exp Rheumatol; 2017; 35(4):638-646. PubMed ID: 28516872
[TBL] [Abstract][Full Text] [Related]
24. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
[TBL] [Abstract][Full Text] [Related]
25. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.
Kojima T; Yabe Y; Kaneko A; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Asai S; Hirabara S; Asai N; Hirano Y; Hayashi M; Miyake H; Kojima M; Ishiguro N
Rheumatology (Oxford); 2015 Jan; 54(1):113-20. PubMed ID: 25102861
[TBL] [Abstract][Full Text] [Related]
26. Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.
Atsumi T; Fujio K; Yamaoka K; Tomobe M; Kuroyanagi K; Kameda H
Mod Rheumatol; 2018 Sep; 28(5):780-788. PubMed ID: 29251032
[TBL] [Abstract][Full Text] [Related]
27. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Yamasaki S; Nakamura H; Ueki Y; Migita K; Mizokami A; Origuchi T; Aoyagi K; Eguchi K
Mod Rheumatol; 2011 Aug; 21(4):365-9. PubMed ID: 21229375
[TBL] [Abstract][Full Text] [Related]
28. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants.
Inciarte-Mundo J; Ruiz-Esquide V; Hernández MV; Cañete JD; Cabrera-Villalba SR; Ramirez J; Yagüe J; Sanmarti R
Rheumatology (Oxford); 2015 Dec; 54(12):2239-43. PubMed ID: 26242859
[TBL] [Abstract][Full Text] [Related]
29. Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data.
Nakashima Y; Kondo M; Fukuda T; Harada H; Horiuchi T; Ishinishi T; Jojima H; Kuroda K; Miyahara H; Maekawa M; Nishizaka H; Nagamine R; Nakashima H; Otsuka T; Shono E; Suematsu E; Shimauchi T; Tsuru T; Wada K; Yoshizawa S; Yoshizawa S; Iwamoto Y
Mod Rheumatol; 2014 Mar; 24(2):258-64. PubMed ID: 24593201
[TBL] [Abstract][Full Text] [Related]
30. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study.
Nishimoto N; Amano K; Hirabayashi Y; Horiuchi T; Ishii T; Iwahashi M; Iwamoto M; Kohsaka H; Kondo M; Matsubara T; Mimura T; Miyahara H; Ohta S; Saeki Y; Saito K; Sano H; Takasugi K; Takeuchi T; Tohma S; Tsuru T; Ueki Y; Yamana J; Hashimoto J; Matsutani T; Murakami M; Takagi N
Mod Rheumatol; 2014 Jan; 24(1):17-25. PubMed ID: 24261754
[TBL] [Abstract][Full Text] [Related]
31. [Effectiveness, therapeutic maintenance and reasons for stopping tocilizumab (TCZ): A retrospective and monocentric study in 88 patients followed for rheumatoid arthritis (RA) at the Reims university hospital].
Chopin C; Pauvele L; Jaulerry S; Brochot P; Eschard JP; Salmon JH
Therapie; 2018; 73(3):231-236. PubMed ID: 29146040
[TBL] [Abstract][Full Text] [Related]
32. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
33. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study.
Nishimoto N; Amano K; Hirabayashi Y; Horiuchi T; Ishii T; Iwahashi M; Iwamoto M; Kohsaka H; Kondo M; Matsubara T; Mimura T; Miyahara H; Ohta S; Saeki Y; Saito K; Sano H; Takasugi K; Takeuchi T; Tohma S; Tsuru T; Ueki Y; Yamana J; Hashimoto J; Matsutani T; Murakami M; Takagi N
Mod Rheumatol; 2014 Jan; 24(1):26-32. PubMed ID: 24261755
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data.
Paul SK; Montvida O; Best JH; Gale S; Pethoe-Schramm A; Sarsour K
Semin Arthritis Rheum; 2018 Feb; 47(4):478-484. PubMed ID: 28947313
[TBL] [Abstract][Full Text] [Related]
35. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge EM; Pavelka K; Nordström DC; Canhão H; Tomšič M; van Vollenhoven R; Gabay C
Rheumatology (Oxford); 2016 Feb; 55(2):230-6. PubMed ID: 26316581
[TBL] [Abstract][Full Text] [Related]
36. Rapid improvement of Clinical Disease Activity Index (CDAI) at 3 months predicts a preferable CDAI outcome at 1 year in active rheumatoid arthritis patients treated with tocilizumab: results from an observational investigation of daily clinical practice.
Kawashiri SY; Nishino A; Suzuki T; Nakashima Y; Horai Y; Ueki Y; Aramaki T; Fujikawa K; Nakashima M; Okada A; Migita K; Mizokami A; Matsuoka N; Mine M; Sakito S; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Aoyagi K; Eguchi K; Kawakami A
Clin Exp Rheumatol; 2016; 34(5):808-812. PubMed ID: 27384149
[TBL] [Abstract][Full Text] [Related]
37. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis.
Maldonado-Montoro M; Cañadas-Garre M; González-Utrilla A; Plaza-Plaza JC; Calleja-Hernández MŸ
Pharmacol Res; 2016 Sep; 111():264-271. PubMed ID: 27339827
[TBL] [Abstract][Full Text] [Related]
38. Tocilizumab, an anti-interleukin-6 receptor antibody, efficiently ameliorates persistent joint inflammation in rheumatoid arthritis.
Hirabayashi Y
Mod Rheumatol; 2021 Jan; 31(1):70-79. PubMed ID: 32342712
[TBL] [Abstract][Full Text] [Related]
39. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
Ogata A; Amano K; Dobashi H; Inoo M; Ishii T; Kasama T; Kawai S; Kawakami A; Koike T; Miyahara H; Miyamoto T; Munakata Y; Murasawa A; Nishimoto N; Ogawa N; Ojima T; Sano H; Shi K; Shono E; Suematsu E; Takahashi H; Tanaka Y; Tsukamoto H; Nomura A;
J Rheumatol; 2015 May; 42(5):799-809. PubMed ID: 25834203
[TBL] [Abstract][Full Text] [Related]
40. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
McLaughlin M; Östör A
Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
